NASDAQ:ZVRA - Nasdaq - US4884452065 - Common Stock - Currency: USD
8.33
-0.12 (-1.42%)
The current stock price of ZVRA is 8.33 USD. In the past month the price increased by 15.21%. In the past year, price increased by 79.14%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 52.28 | 681.79B | ||
JNJ | JOHNSON & JOHNSON | 15.17 | 366.76B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.22 | 304.82B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.46 | 220.95B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16 | 218.21B | ||
MRK | MERCK & CO. INC. | 9.78 | 191.27B | ||
PFE | PFIZER INC | 7.22 | 131.79B | ||
SNY | SANOFI-ADR | 11.79 | 126.53B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.4 | 95.59B | ||
GSK | GSK PLC-SPON ADR | 8.84 | 79.50B | ||
ZTS | ZOETIS INC | 27.48 | 73.64B | ||
HLN | HALEON PLC-ADR | 22.96 | 50.66B |
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 59 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
ZEVRA THERAPEUTICS INC
1180 Celebration Boulevard, Suite 103
Celebration FLORIDA US
Employees: 59
Phone: 13219393416
The current stock price of ZVRA is 8.33 USD. The price decreased by -1.42% in the last trading session.
The exchange symbol of ZEVRA THERAPEUTICS INC is ZVRA and it is listed on the Nasdaq exchange.
ZVRA stock is listed on the Nasdaq exchange.
14 analysts have analysed ZVRA and the average price target is 22.73 USD. This implies a price increase of 172.89% is expected in the next year compared to the current price of 8.33. Check the ZEVRA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ZEVRA THERAPEUTICS INC (ZVRA) has a market capitalization of 455.48M USD. This makes ZVRA a Small Cap stock.
ZEVRA THERAPEUTICS INC (ZVRA) currently has 59 employees.
ZEVRA THERAPEUTICS INC (ZVRA) has a support level at 8.32 and a resistance level at 8.54. Check the full technical report for a detailed analysis of ZVRA support and resistance levels.
The Revenue of ZEVRA THERAPEUTICS INC (ZVRA) is expected to grow by 325.15% in the next year. Check the estimates tab for more information on the ZVRA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ZVRA does not pay a dividend.
ZEVRA THERAPEUTICS INC (ZVRA) will report earnings on 2025-08-11, before the market open.
ZEVRA THERAPEUTICS INC (ZVRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.92).
The outstanding short interest for ZEVRA THERAPEUTICS INC (ZVRA) is 10.42% of its float. Check the ownership tab for more information on the ZVRA short interest.
ChartMill assigns a technical rating of 8 / 10 to ZVRA. When comparing the yearly performance of all stocks, ZVRA is one of the better performing stocks in the market, outperforming 94.28% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ZVRA. ZVRA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ZVRA reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS decreased by -42.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -53.26% | ||
ROE | -224.24% | ||
Debt/Equity | 1.46 |
ChartMill assigns a Buy % Consensus number of 84% to ZVRA. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 129.85% and a revenue growth 325.15% for ZVRA